353238-51-4 Usage
General Description
2-(1-Methylcyclopropyl)-1,3,4-oxadiazole is a heterocyclic compound with the chemical formula C6H8N2O. It is a five-membered ring containing one oxygen and two nitrogen atoms. 2-(1-Methylcyclopropyl)-1,3,4-oxadiazole is primarily used in the pharmaceutical industry as a building block for the synthesis of various potentially bioactive compounds. It has also been studied for its potential use as a pesticide, as it has shown insecticidal and acaricidal properties against a variety of pests. Additionally, 2-(1-Methylcyclopropyl)-1,3,4-oxadiazole has been investigated for its potential anti-inflammatory and analgesic properties, making it a versatile compound with potential applications in various fields.
Check Digit Verification of cas no
The CAS Registry Mumber 353238-51-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,5,3,2,3 and 8 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 353238-51:
(8*3)+(7*5)+(6*3)+(5*2)+(4*3)+(3*8)+(2*5)+(1*1)=134
134 % 10 = 4
So 353238-51-4 is a valid CAS Registry Number.
InChI:InChI=1/C6H8N2O/c1-6(2-3-6)5-8-7-4-9-5/h4H,2-3H2,1H3
353238-51-4Relevant articles and documents
Development of orally active nonpeptidic inhibitors of human neutrophil elastase
Ohmoto,Yamamoto,Okuma,Horiuchi,Imanishi,Odagaki,Kawabata,Sekioka,Hirota,Matsuoka,Nakai,Toda,Cheronis,Spruce,Gyorkos,Wieczorek
, p. 1268 - 1285 (2007/10/03)
5-Amino-2-phenylpyrimidin-6-ones, some of their desamino derivatives, and miscellaneous derivatives were synthesized and biologically evaluated on both in vitro activity and oral activity in an acute hemorrhagic assay. These compounds contained an α-keto-1,3,4-oxadiazole moiety to bind covalently to the Ser-195 hydroxy group of human neutrophil elastase (HNE). Among those tested, compounds 11a-c,e,i-l(F), 11d,e,k(H), 21d,e,k(F), and 21d,e(H) showed a good oral profile. RS-Mixture 3(H) was selected for clinical evaluation based on its oral potency, duration of action, enzyme selectivity, safety profile, and ease of synthesis. Structure -activity relationships (SARs) are discussed.
